Advertisement

dt-jc Created with Sketch.
dt-jc Created with Sketch.

Advances in Psoriasis Treatment: IL-17 Inhibitors

Jeffery Weinberg, MD, Joshua Zeichner, MD, FAAD

Jeffery Weinberg, MD sits down with host Josh Zeichner, MD to discuss what he describes as a second revolution in the biologic therapy to treat psoriasis. Specifically, he discusses the effectiveness of a new class of biologics, IL-17 inhibitors, including first-in-class secukinumab and the recently approved ixekizumab, as well as brodalumab, which is expected to be approved soon. Dr. Weinberg discusses efficacy, dosing, patient selection, and safety profiles.

Advertisement

In This Series

View More

Advertisement